Cocrystal Pharma to Present at the Noble Capital Markets’ NobleCon18 Conference

Rhea-AI Summary

Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that James Martin, Chief Financial Officer and co-interim CEO, will present at the NobleCon18 Investor Conference on April 21, 2022, at 9:30 a.m. ET, held at the Hard Rock Hotel & Casino in Hollywood, Florida. A video webcast of the presentation will be available the next day on the Company's website, as well as on Noble Capital Markets’ and Channelchek's websites, archived for 90 days.

Cocrystal, a clinical-stage biotechnology company, focuses on developing novel antiviral therapeutics targeting various viruses.

BOTHELL, Wash., April 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a Company overview at the NobleCon18—Noble Capital Markets’ Eighteenth Annual Investor Conference on Thursday, April 21, 2022 at 9:30 a.m. Eastern Time. The conference is being held at the Hard Rock Hotel & Casino in Hollywood, Fla.

A video webcast of the presentation will be available the following day on the Company's website, as well as at the Noble Capital Markets’ Conference website and on the Channelchek website. The webcast will be archived for 90 days following the event.

About Noble Capital Markets, Inc.
Noble Capital Markets is a research-driven investment bank that has supported small and microcap companies since 1984. As a FINRA and SEC licensed broker dealer, Noble provides institutional-quality equity research, merchant and investment banking, and order execution services. In 2005, Noble established NobleCon, an investor conference that has grown substantially over the past decade. In 2018, Noble launched Channelchek—an investor community dedicated exclusively to public small and micro-cap companies and their industries. Channelchek is the first service to offer institutional-quality research to the public for free without a subscription.

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

Media Contact:
JQA Partners
Jules Abraham
917-885-7378
Jabraham@jqapartners.com

# # #

FAQ

When will Cocrystal Pharma present at the NobleCon18 Investor Conference?

Cocrystal Pharma will present at the NobleCon18 Investor Conference on April 21, 2022, at 9:30 a.m. Eastern Time.

Who is presenting for Cocrystal Pharma at the conference?

James Martin, CFO and co-interim CEO, will be presenting for Cocrystal Pharma.

Where is the NobleCon18 Investor Conference being held?

The conference is being held at the Hard Rock Hotel & Casino in Hollywood, Florida.

Will the presentation be available online after the event?

Yes, a video webcast of the presentation will be available the following day on Cocrystal's website and other platforms, archived for 90 days.

What is the focus of Cocrystal Pharma's research?

Cocrystal Pharma focuses on discovering and developing antiviral therapeutics targeting influenza viruses, coronaviruses, hepatitis C, and noroviruses.